Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | TEK | Q02763 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29915423 | 0.89 | MAPT (0.46) | MAPTHDAC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29915381 | 0.88 | MAPT (0.41) | MAPTTP53HDAC1SMN1; SMN2MEN1 | |
| SCHEMBL20600063 | 0.87 | MAPT (0.45) | MAPTTP53KDREPHB4TEK | |
| SCHEMBL29915468 | 0.87 | PTGDR (0.42) | MAPTSMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL29915480 | 0.84 | TP53 (0.44) | MAPTTP53MAPK1MAPK10GCGR | |
| SCHEMBL29915535 | 0.84 | MAPT (0.41) | MAPTHDAC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29915488 | 0.83 | MAPT (0.42) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22613601 | 0.82 | MAPT (0.44) | MAPTTP53KDREPHB4TEK | |
| SCHEMBL22613652 | 0.81 | MAPT (0.44) | MAPTTP53KDREPHB4TEK | |
| SCHEMBL22613710 | 0.76 | MAPT (0.45) | MAPTTP53HDAC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11440922-B2 | Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors | Recordati Industria Chimica e Farmacentica S.p.A. (IT) | 2022-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440922-B2 | Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors | GRM5, GRIK5, GRM2 | MAPT 361/4885TP53 4499/4885KDR 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.